Coston McIsaac & Partners’s Moderna MRNA Stock Holding History

Coston McIsaac & Partners’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7K	Sell	109 -250	-70%	-$12.9K	﹤0.01%	642
2026 Q1	$18K	Buy	359 +250	+229%	+$11.7K	﹤0.01%	487
2025 Q4	$3K	Hold	109	–	–	﹤0.01%	719
2025 Q3	$2K	Hold	109	–	–	﹤0.01%	724
2025 Q2	$3K	Sell	109 -1,170	-91%	-$30.8K	﹤0.01%	663
2025 Q1	$36K	Buy	1,279 +1,160	+975%	+$41.2K	0.01%	326
2024 Q4	$4K	Hold	119	–	–	﹤0.01%	612
2024 Q3	$7K	Sell	119 -20	-14%	-$1.84K	﹤0.01%	556
2024 Q2	$16K	Hold	139	–	–	0.01%	406
2024 Q1	$14K	Hold	139	–	–	﹤0.01%	437
2023 Q4	$13K	Hold	139	–	–	﹤0.01%	449
2023 Q3	$14K	Hold	139	–	–	0.01%	424
2023 Q2	$16K	Hold	139	–	–	0.01%	442
2023 Q1	$21K	Hold	139	–	–	0.01%	394
2022 Q4	$24K	Hold	139	–	–	0.01%	383
2022 Q3	$16K	Sell	139 -7	-5%	-$1.06K	0.01%	358
2022 Q2	$21K	Buy	+146	New	+$20.9K	0.01%	201

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Coston McIsaac & Partners's MRNA Position: Q2 2026 in Review

Coston McIsaac & Partners reduced its Moderna (MRNA) stake by 70% in Q2 2026, selling an estimated $12.9K and leaving 109 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #642.

Coston McIsaac & Partners first reported a position in MRNA in Q2 2022 and has held it in 17 quarters since. The position peaked at $36K in Q1 2025. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Coston McIsaac & Partners held 109 shares of Moderna worth $7K as of Q2 2026.
Coston McIsaac & Partners sold 250 Moderna shares in Q2 2026, an estimated $12.9K.
Moderna made up ﹤0.01% of Coston McIsaac & Partners's portfolio in Q2 2026, its #642 holding.
Coston McIsaac & Partners first reported a position in Moderna in Q2 2022 and has held it in 17 quarters since.
Coston McIsaac & Partners's Moderna position peaked at $36K in Q1 2025.
780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Coston McIsaac & Partners's 13F filing for Q2 2026, filed 12 Aug 2026.